Things may soon go from bad to worse for Under Armour Inc (NYSE: UAA) investors. Despite the fact that Under Armour stock is down roughly 50 percent in
the past year, Bank of America has downgraded the stock from Neutral to Underperform and sees additional
downside of about 25 percent from current levels.
On Monday morning, analyst Robert Ohmes said international growth
opportunities are simply not strong enough for Under Armour to offset its North American problems. According to Ohmes, investors
should be prepared for Under Armour to lower its fourth-quarter guidance when it reports Q3 earnings Tuesday.
Ohmes sees four major headwinds for Under Armour at the moment:
- Key Under Armour retailers, including Dicks Sporting Goods Inc (NYSE: DKS), Foot Locker, Inc. (NYSE: FL) and Hibbett Sports, Inc. (NASDAQ: HIBB), are all having terrible
years and showing few signs of improvement.
- The highly promotional environment is weighing on sporting goods margins.
- Footwear sell-through data has been discouraging.
- Expanding Under Armour distribution to lower-tier channels, such as Kohl’s Corporation (NYSE: KSS) and Famous Footwear, has negatively impacted the Under Armour brand.
Under Armour bulls have pointed to the relatively untapped international market as a means for the company to return to
20-percent revenue growth. However, Ohmes said even 50-percent growth in the international business in Q4 will not be good enough
for Under Armour to hit its overall revenue target for the quarter. International sales made up only about 15 percent of the
company’s overall sales in 2016.
In addition to the downgrade, Bank of America now has a $12 price target for Under Armour stock.
Related Link: Vetr
Issues Hold On Under Armour Following A Short-Lived Analyst Bump
Latest Ratings for UAA
Date |
Firm |
Action |
From |
To |
Oct 2017 |
Bank of America |
Downgrades |
Neutral |
Underperform |
Oct 2017 |
Deutsche Bank |
Maintains |
|
Sell |
Oct 2017 |
Canaccord Genuity |
Maintains |
|
Hold |
View More Analyst Ratings for
UAA
View the Latest Analyst Ratings
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.